COMPANY:

Eone Diagnomics Genome Center

"EONE-Diagnomics Genome Center (EDGC)...said Friday that its clinical testing laboratory in Incheon had obtained the Clinical Laboratory Improvement Amendments (CLIA) certification in the U.S...With the acquisition of CLIA certification, EDGC will be able to directly test clinical specimens collected from the U.S. in its laboratory and provide related test results to medical institutions and hospitals in the U.S."

"EDGC (Eone Diagnomics Genome Center) said has successfully completed its acquisition of GDXLab, a CLIA (Clinical Laboratory Improvement Amendments) certified lab located in the southern part of Denver, Colorado...The acquisition of GDXLab is the latest achievement in EDGC’s efforts to expand into the North American market as the company recently received export permission for OncoCatch-E, a colon cancer diagnostic kit, from the Ministry of Food and Drug Safety..."

"EDGC (Eone Diagnomics) announced today the groundbreaking results of their study on cancer diagnosis, showcasing the significant accuracy improvement achieved through their state-of-the-art multi-omics genome analysis platform powered by artificial intelligence (AI) technology."

"Eone-Diagnomics Genome Center (EDGC) is on the verge of launching a blood-based multi-cancer early detection test that the firm hopes to ramp up in coming years to detect dozens of cancer types and potentially non-cancer applications such as Alzheimer's progression...The South Korea-based joint venture between bioinformatics firm Diagnomics and clinical laboratory firm Eone Laboratories says it plans to launch its OncoCatch-E epigenetic liquid biopsy assay by early 2024 as a laboratory-developed test that would compete in the emerging MCED market."

"EONE-Diagnomics Genome Center (EDGC)...said that it launched its liquid biopsy business in Vietnam in collaboration with CHEK Genomics...EDGC will provide best-in-class clinical services to CHEK Genomics' Vietnamese patients and validate the efficacy and accuracy of EDGC's liquid biopsy, ONCOCATCH. EDGC plans to also commercialize various services and products based on its cancer-related liquid biopsy and genetic testing technologies."